FebriDx® Rollout Gains Momentum with 43 New WellStreet Locations
1 May 2026
Following the success of their initial program and supported by the recent granting of CLIA waiver for FebriDx®, WellStreet has now begun testing at 43 additional sites, drawn from WellStreet’s network of 165 urgent care locations throughout the US. This expansion is comprised of additional centers in the Fayetteville District (8 locations), a second Georgia District in the East (7 locations) and the entire Michigan market (28 locations).
As previously announced, the expectation is to launch FebriDx in the remaining WellStreet Urgent Care locations over the next 6-12 months. Under a standing order protocol implemented as part of the expanded program, FebriDx® will be offered to every patient presenting with ARI symptoms. Test results will be available to the provider prior to entering the examination room, enabling faster clinical decision‑making and more timely diagnosis and treatment of patients.
As previously announced, the expectation is to launch FebriDx in the remaining WellStreet Urgent Care locations over the next 6-12 months. Under a standing order protocol implemented as part of the expanded program, FebriDx® will be offered to every patient presenting with ARI symptoms. Test results will be available to the provider prior to entering the examination room, enabling faster clinical decision‑making and more timely diagnosis and treatment of patients.
